Resistance to cisplatin treatment in HCC

Oncology Reports

Volumn 34, Issue 6, 2015, Pages 3297-3303

  Ding, Kun ^a,b   Fan, Lu ^b   Chen, Shijun ^a   Wang, Yanna ^b   Yu, Haifeng ^b   Sun, Yanni ^b   Yu, Jiguang ^b   Wang, Li ^b   Liu, Xiangzhong ^b   Liu, Youde ^b  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Infectious Disease Hospital of Yantai   (China)

Author keywords

Apoptosis; Cisplatin resistance; Hepatocellular carcinoma; Osteopontin; PI3K AKT signaling pathway

Indexed keywords

CASPASE 3; CISPLATIN; HERMES ANTIGEN; MESSENGER RNA; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; VITRONECTIN RECEPTOR; ONCOPROTEIN;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CARCINOMA CELL; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL CARCINOMA; OPN GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; UPREGULATION; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; DRUG RESISTANCE; GENETICS; LIVER NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; ONCOGENE PROTEIN V-AKT; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 84943795961     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4306     Document Type: Article

References (44)

1. Venook AP, Papandreou C, Furuse J and de Guevara LL: The incidence and epidemiology of hepatocellular carcinoma: A global and regional perspective. Oncologist 15 (Suppl 4): 5-13, 2010.
2. Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF and Altekruse SF: Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database. United European Gastroenterol J 1: 351-357, 2013.
3. J aka H, Mshana SE, Rambau PF, Masalu N, Chalya PL and Kalluvya SE: Hepatocellular carcinoma: Clinicopathological profile and challenges of management in a resource-limited setting. World J Surg Oncol 12: 246, 2014.
4. Naugler WE, Alsina AE, Frenette CT, Rossaro L and Sellers MT: Building the multidisciplinary team for management of patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 13: 827-835, 2014.
5. Crissien AM and Frenette C: Current management of hepatocellular carcinoma. Gastroenterol Hepatol (NY) 10: 153-161, 2014.
6. Knudsen ES, Gopal P and Singal AG: The changing landscape of hepatocellular carcinoma: Etiology, genetics, and therapy. Am J Pathol 184: 574-583, 2014.
7. Kew MC: The role of cirrhosis in the etiology of hepatocellular carcinoma. J Gastrointest Cancer 45: 12-21, 2014.
8. Tornai I: Role of environmental factors in the etiology of hepatocellular carcinoma. Orv Hetil 151: 1132-1136, 2010 (in Hungarian).
9. Senkerikova R, Frankova S, Sperl J, Oliverius M, Kieslichova E, Filipova H, Kautznerova D, Honsova E, Trunecka P and Spicak J: Incidental hepatocellular carcinoma: Risk factors and long-term outcome after liver transplantation. Transplant Proc 46: 1426-1429, 2014.
10. Kamiyama T, Tahara M, Nakanishi K, Yokoo H, Kamachi H, Kakisaka T, Tsuruga Y, Matsushita M and Todo S: Long-term outcome of laparoscopic hepatectomy in patients with hepatocellular carcinoma. Hepatogastroenterology 61: 405-409, 2014.
11. Takaki S, Sakaguchi H, Anai H, Tanaka T, Yamamoto K, Morimoto K, Nishiofuku H, Inoue M, Sueyoshi S, Nagata T, et al: Long-term outcome of transcatheter subsegmental and segmental arterial chemoemobolization using lipiodol for hepatocellular carcinoma. Cardiovasc Intervent Radiol 35: 544-554, 2012.
12. Otsuji K, Takai K, Nishigaki Y, Shimizu S, Hayashi H, Imai K, Suzuki Y, Hanai T, Ideta T, Miyazaki T, et al: Efficacy and safety of cisplatin versus miriplatin in transcatheter arterial chemoembolization and transarterial infusion chemotherapy for hepatocellular carcinoma: A randomized controlled trial. Hepatol Res 45: 514-522, 2014.
13. Ishikawa T, Kubota T, Abe S, Watanabe Y, Sugano T, Inoue R, Iwanaga A, Seki K, Honma T and Yoshida T: Hepatic arterial infusion chemotherapy with cisplatin before radical local treatment of early hepatocellular carcinoma (JIS score 0/1) improves survival. Ann Oncol 25: 1379-1384, 2014.
14. Terazawa T, Kondo S, Hosoi H, Morizane C, Shimizu S, Mitsunaga S, Ikeda M, Ueno H and Okusaka T: Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: A phase I trial. BMC Cancer 14: 301, 2014.
15. An J, Wang X, Guo P, Zhong Y, Zhang X and Yu Z: Hexabromocyclododecane and polychlorinated biphenyls increase resistance of hepatocellular carcinoma cells to cisplatin through the phosphatidylinositol 3-kinase/protein kinase Bpathway. Toxicol Lett 229: 265-272, 2014.
16. Fang D, Guo Y, Zhu Z and Chen W: Silence of p15 expression by RNAi enhances cisplatin resistance in hepatocellular carcinoma cells. Bosn J Basic Med Sci 12: 4-9, 2012.
17. Kim Y, Jang M, Lim S, Won H, Yoon KS, Park JH, Kim HJ, Kim BH, Park WS, Ha J, et al: Role of cyclophilin Bin tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans. Hepatology 54: 1661-1678, 2011.
18. Butler WT: Structural and functional domains of osteopontin. Ann NY Acad Sci 760: 6-11, 1995.
19. Dai J, Cao Z, Kang Y, Fan K, Ji G, Yang H, Wang H, Gao J, Wang H and Guo Y: A functional motif QLYxxYP is essential for osteopontin induced T lymphocyte activation and migration. Biochem Biophys Res Commun 380: 715-720, 2009.
20. Cao Z, Dai J, Fan K, Wang H, Ji G, Li B, Zhang D, Hou S, Qian W, Zhao J, et al: A novel functional motif of osteopontin for human lymphocyte migration and survival. Mol Immunol 45: 3683-3692, 2008.
21. Kumar S, Sharma P, Kumar D, Chakraborty G, Gorain M and Kundu GC: Functional characterization of stromal osteopontin in melanoma progression and metastasis. PLoS One 8: e69116, 2013.
22. Yu M, Liu Q, Yi K, Wu L and Tan X: Effects of osteopontin on functional activity of late endothelial progenitor cells. J Cell Biochem 112: 1730-1736, 2011.
23. Qiu Y, Hu Y, Zhang ZY, Ye L, Xu FH, Schneider ME, Ma XL, Du YX, Zuo XB, Zhou FS, et al: Genetic association of osteopontin (OPN) and its receptor CD44 genes with susceptibility to Chinese gastric cancer patients. J Cancer Res Clin Oncol 140: 2143-2156, 2014.
24. Liu J, Liu Q, Wan Y, Zhao Z, Yu H, Luo H and Tang Z: Osteopontin promotes the progression of gastric cancer through the NF-κB pathway regulated by the MAPK and PI3K. Int J Oncol 45: 282-290, 2014.
25. Pang H, Lu H, Song H, Meng Q, Zhao Y, Liu N, Lan F, Liu Y, Yan S, Dong X, et al: Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer. Cancer Epidemiol 37: 985-992, 2013.
26. Zhang H, Guo M, Chen JH, Wang Z, Du XF, Liu PX and Li WH: Osteopontin knockdown inhibits αv,β3 integrin-induced cell migration and invasion and promotes apoptosis of breast cancer cells by inducing autophagy and inactivating the PI3K/Akt/ mTOR pathway. Cell Physiol Biochem 33: 991-1002, 2014.
27. Hsieh IS, Huang WH, Liou HC, Chuang WJ, Yang RS and Fu WM: Upregulation of drug transporter expression by osteopontin in prostate cancer cells. Mol Pharmacol 83: 968-977, 2013.
28. Thoms JW, Dal Pra A, Anborgh PH, Christensen E, Fleshner N, Menard C, Chadwick K, Milosevic M, Catton C, Pintilie M, et al: Plasma osteopontin as a biomarker of prostate cancer aggression: Relationship to risk category and treatment response. Br J Cancer 107: 840-846, 2012.
29. Zhang T, Zhang DM, Zhao D, Hou XM, Liu XJ, Ling XL and Ma SC: The prognostic value of osteopontin expression in non-small cell lung cancer: A meta-analysis. J Mol Histol 45: 533-540, 2014.
30. Yu TT, Han ZG, Shan L, Tao J, Zhang T, Yuan SF and Shen HL: Expression of osteopontin in non-small cell lung cancer and correlative relation with microvascular density. Asian Pac J Cancer Prev 15: 29-32, 2014.
31. El-Din Bessa SS, Elwan NM, Suliman GA and El-Shourbagy SH: Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis Cvirus-related hepatocellular carcinoma. Arch Med Res 41: 541-547, 2010.
32. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA and Beretta L: Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 55: 483-490, 2012.
33. Kim SH, Chung YH, Yang SH, Kim JA, Jang MK, Kim SE, Lee D, Lee SH, Lee D, Kim KM, et al: Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization. Korean J Hepatol 15: 320-330, 2009.
34. Phillips RJ, Helbig KJ, Van der Hoek KH, Seth D and Beard MR: Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner. World J Gastroenterol 18: 3389-3399, 2012.
35. Yu MC, Lee YS, Lin SE, Wu HY, Chen TC, Lee WC, Chen MF and Tsai CN: Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann Surg Oncol 19 (Suppl 3): S455-S463, 2012.
36. Daniele B: Current issues in the management of hepatocellular carcinoma. Ann Oncol 24 (Suppl 2): ii5, 2013.
37. Qin L: Osteopontin is a promoter for hepatocellular carcinoma metastasis: A summary of 10 years of studies. Front Med 8: 24-32, 2014.
38. Zhang R, Pan X, Huang Z, Weber GF and Zhang G: Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/ CXCR4 axis in hepatocellular carcinoma cell lines. PLoS One 6: e23831, 2011.
39. Lin F, Li Y, Cao J, Fan S, Wen J, Zhu G, Du H and Liang Y: Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells. Mol Biol Rep 38: 5205-5210, 2011.
40. Chen RX, Xia YH, Xue TC, Zhang H and Ye SL: Downregulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA. Oncol Rep 25: 803-808, 2011.
41. Cheng L, Luo S, Jin C, Ma H, Zhou H and Jia L: FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell Death Dis 4: e923, 2013.
42. Wang XJ, Feng CW and Li M: ADAM17 mediates hypoxiainduced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway. Mol Cell Biochem 380: 57-66, 2013.
43. Li QL, Gu FM, Wang Z, Jiang JH, Yao LQ, Tan CJ, Huang XY, Ke AW, Dai Z, Fan J, et al: Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma. PLoS One 7: e33379, 2012.
44. Gu T, Ohashi R, Cui R, Tajima K, Yoshioka M, Iwakami S, Sasaki S, Shinohara A, Matsukawa T, Kobayashi J, et al: Osteopontin is involved in the development of acquired chemoresistance of cisplatin in small cell lung cancer. Lung Cancer 66: 176-183, 2009.